Advertising, free-riding, and price differences in the market for prescription drugs

B.E. Journal of Economic Analysis and Policy

Volumn 8, Issue 2, 2008, Pages

  Linnosmaa, Ismo Erkki ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Advertising; Pharmaceuticals; Pricing

Indexed keywords

EID: 48749107975     PISSN: None     EISSN: 19351682     Source Type: Journal    
DOI: 10.2202/1935-1682.1819     Document Type: Article

References (24)

1. Berndt E.R. (2002) Pharmaceuticals in US health care: Determinants of quantity and price, Journal of Economic Perspectives, 16(4), 45-66.
2. Berndt E.R., L. Bui, D.R. Reiley and G.L. Urban (1995) Information, marketing, and pricing in the US Antiulcer drug market, American Economic Review, Papers and Proceedings, 85(2), 100-105.
3. Brekke K.R. and M. Kuhn (2006) Direct to consumer advertising in pharmaceutical markets, Journal of Health Economics, 25(1), 102-130.
4. Butters G.R. (1977) Equilibrium distributions of sales and advertising prices, Review of Economic Studies, 44(3), 465-491.
5. Caves R.E., M.D. Whinston and M.A. Hurwitz (1991) Patent expiration, entry, and competition in the US pharmaceutical industry, Brooking Papers on Economic Activity, Microeconomics, Vol.1991, 1-66.
6. Dasgupta P. and E. Maskin (1986) The existence of equilibrium in discontinuous economic games, I: Theory, The Review of Economic Studies, 53(1), 1-26.
7. Frank R.G. and D.S. Salkever (1992) Pricing, patent loss and the market for pharmaceuticals, Southern Economic Journal, 59(2), 165-179.
8. Frank R.G. and D.S. Salkever (1997) Generic entry and the pricing of pharmaceuticals, Journal of Economics and Management Strategy, 6(1), 75-90.
9. Grabowski H.G. and J.M. Vernon (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act, Journal of Law and Economics, 35(2), 331-350.
10. Grossman G.M. and C. Shapiro (1984) Informative advertising with differentiated products, The Review of Economic Studies, 51(1), 63-81.
11. Hurwitz M.A. and R.E. Caves (1988) Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals, Journal of Law and Economics, 31(2), 299-320.
12. Iizuka T. and G.Z. Jin (2005) The effect of prescription drug advertising on doctor visits, Journal of Economics and Management Strategy, 14(3), 701-727.
13. Königbauer I. (2007) Advertising and generic market entry, Journal of Health Economics, 26(2), 286-305.
14. Mas-Colell A., M.D. Whinston and J.R. Green (1995) Microeconomic Theory. Oxford University Press, New York, New York.
15. Rizzo J.A. (1999) Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs, Journal of Law and Economics 42(1), 89-116.
16. Rosenthal M.B., E.R. Berndt, J.M. Donohue, A.M. Epstein and R.G. Frank (2003) Demand effects of recent changes in prescription drug promotion, Chapter in Cutler D.M. and A.M. Garber (eds.) Frontiers in Health Policy Research 2003, Vol. 6, 1-26. The MIT Press, Cambridge, Massachusetts.
17. Scherer F.M. (2000) The pharmaceutical industry, Chapter in Culyer, A.J and J.P. Newhouse (eds.) Handbook of Health Economics 2000, Vol. 1B, 1297-1332. Elsevier B.V., Amsterdam, The Netherlands.
18. Scott Morton F.M. (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry, International Journal of Industrial Organization 18(7), 1085-1104.
19. Shaked A. and J. Sutton (1982) Relaxing price competition through product differentiation, The Review of Economic Studies, 49(1), 3-13.
20. Shaked A. and J. Sutton (1983) Natural oligopolies, Econometrica, 51(5), 1469-1483.
21. Stigler G.J. and G.S. Becker (1977) De gustibus non est disbutandum, The American Economic Review, 67(2), 76-90.
22. Sutton J. (1991) Sunk Costs and Market Structure. Price Competition, Advertising, and the Evolution of Concentration. The MIT Press, Cambridge, Massachusetts.
23. Wauthy X. (1996) Quality choice in the models of vertical differentiation, The Journal of Industrial Economics, XLIV(3), 345-353.
24. Windmeijer F., E. de Laat, R. Douven and E. Mot (2006) Pharmaceutical promotion and GP prescription behavior, Health Economics, 15(1), 5-18.